IL267451B2 - Benzodiazepine derivatives, compounds, and methods for treating cognitive impairment - Google Patents

Benzodiazepine derivatives, compounds, and methods for treating cognitive impairment

Info

Publication number
IL267451B2
IL267451B2 IL267451A IL26745119A IL267451B2 IL 267451 B2 IL267451 B2 IL 267451B2 IL 267451 A IL267451 A IL 267451A IL 26745119 A IL26745119 A IL 26745119A IL 267451 B2 IL267451 B2 IL 267451B2
Authority
IL
Israel
Prior art keywords
alkyl
aryl
aliphatic
membered heteroaryl
pct
Prior art date
Application number
IL267451A
Other languages
English (en)
Hebrew (he)
Other versions
IL267451B1 (en
IL267451A (en
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Publication of IL267451A publication Critical patent/IL267451A/en
Publication of IL267451B1 publication Critical patent/IL267451B1/en
Publication of IL267451B2 publication Critical patent/IL267451B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL267451A 2016-12-19 2017-12-20 Benzodiazepine derivatives, compounds, and methods for treating cognitive impairment IL267451B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436272P 2016-12-19 2016-12-19
US2017067448 2017-12-19
PCT/IB2017/001762 WO2018130868A1 (en) 2016-12-19 2017-12-20 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Publications (3)

Publication Number Publication Date
IL267451A IL267451A (en) 2019-08-29
IL267451B1 IL267451B1 (en) 2023-06-01
IL267451B2 true IL267451B2 (en) 2023-10-01

Family

ID=62557208

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267451A IL267451B2 (en) 2016-12-19 2017-12-20 Benzodiazepine derivatives, compounds, and methods for treating cognitive impairment

Country Status (10)

Country Link
US (2) US20180170941A1 (enExample)
EP (1) EP3555100B1 (enExample)
JP (1) JP7153938B2 (enExample)
CN (2) CN116640143A (enExample)
AU (1) AU2017393082B2 (enExample)
CA (1) CA3047684A1 (enExample)
EA (1) EA201991497A1 (enExample)
IL (1) IL267451B2 (enExample)
MX (1) MX388726B (enExample)
WO (2) WO2018130869A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2990004C (en) 2015-06-19 2024-04-23 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio, Inc. derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
AU2019288382B2 (en) * 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
MX2022007725A (es) * 2019-12-19 2022-07-19 Agenebio Inc Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.
IL299761A (en) * 2020-07-10 2023-03-01 Agenebio Inc GABAA alpha 5 agonist polymorphs and methods of use for the treatment of cognitive impairment
US20230270753A1 (en) * 2020-07-10 2023-08-31 Agenebio, Inc. Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
CN113413532B (zh) * 2021-07-01 2022-03-01 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统
AU2023324882A1 (en) 2022-08-19 2025-03-20 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040487A2 (en) * 2000-11-16 2002-05-23 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as gaba a receptor modulators
US20060084642A1 (en) * 2004-10-20 2006-04-20 Henner Knust Substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives
WO2012068149A1 (en) * 2010-11-15 2012-05-24 Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
WO2015095783A1 (en) * 2013-12-20 2015-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
NL7305644A (enExample) 1972-04-20 1973-10-23
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
EP0402644B1 (en) 1989-05-19 1995-08-16 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (enExample) * 1991-06-17 1993-03-01 Hoffmann La Roche
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
CA2182981C (en) 1994-03-02 2006-10-17 Leonardus Petrus Carla Delbressine Sublingual or buccal pharmaceutical composition
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
EP1157989B1 (en) 1999-03-03 2004-09-22 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
WO2004037234A2 (en) 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040191803A1 (en) 2002-11-22 2004-09-30 Michela Gallagher Target for therapy of cognitive impairment
TW200526194A (en) 2003-10-22 2005-08-16 Merz Pharma Gmbh & Co Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic Aβ peptides in amyloidopathies
AU2005293820B2 (en) 2004-10-12 2010-11-25 F. Hoffmann-La Roche Ag Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders
RU2007114763A (ru) 2004-10-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) Галогенозамещенные производные бензодиазепинов
EP1828194B1 (en) 2004-12-14 2008-05-28 F. Hoffmann-Roche AG Tetracyclic imidazo-benzodiazepines as gaba receptors modulators
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1924712B1 (en) 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
CA2737452C (en) 2008-09-25 2018-05-22 Vive Nano Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
WO2011085406A1 (en) 2010-01-11 2011-07-14 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
PH12013500676A1 (en) 2010-11-05 2013-05-06 Hoffmann La Roche Use of active pharmaceutical compounds for the treatment of central nervous system conditions
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
US20150224094A1 (en) 2012-09-10 2015-08-13 Ophirex, Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
CA2990004C (en) * 2015-06-19 2024-04-23 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en) * 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2022007725A (es) * 2019-12-19 2022-07-19 Agenebio Inc Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040487A2 (en) * 2000-11-16 2002-05-23 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as gaba a receptor modulators
US20060084642A1 (en) * 2004-10-20 2006-04-20 Henner Knust Substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives
WO2012068149A1 (en) * 2010-11-15 2012-05-24 Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
WO2015095783A1 (en) * 2013-12-20 2015-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACHERMANN, GUIDO ET AL.,, DISCOVERY OF THE IMIDAZO[1,5-A][1,2,4]-TRIAZOLO[1,5- D][I,4]BENZODIAZEPINE SCAFFOLD AS A NOVEL, POTENT AND SELECTIVE GABA A A5 INVERSE AGONIST SERIES, 31 December 2009 (2009-12-31) *
GERECKE. M ET AL.,, NEW TETRACYCLIC DERIVATIVES OF IMIDAZO-[1,5-A][1,4]BENZODIAZEPINES AND OF IMIDAZO[1,5-A]THIENO[3,2-F][1,4]DIAZEPINES, 31 December 1994 (1994-12-31) *
HUSSAIN, M.K. ET AL.,, TANDEM C-2 FUNCTIONALIZATION-INTRAMOLECULAR AZIDE-ALKYNE 1,3- DIPOLAR CYCLOADDITION REACTION: A CONVENIENT ROUTE TO HIGHLY DIVERSIFIED 9H- BENZO[B]PYRROLO[1,2-G]TRIAZOLO[1,5-D][1,4]DIAZEPINES, 31 December 2014 (2014-12-31) *
JONAS, OLIVER ET AL.,, FIRST IN VIVO TESTING OF COMPOUNDS TARGETING GROUP 3 MEDULLOBLASTOMAS USING AN IMPLANTABLE MICRODEVICE AS A NEW PARADIGM FOR DRUG DEVELOPMENT, 31 December 2016 (2016-12-31) *

Also Published As

Publication number Publication date
WO2018130868A1 (en) 2018-07-19
CN116640143A (zh) 2023-08-25
WO2018130869A1 (en) 2018-07-19
AU2017393082A1 (en) 2019-07-25
MX388726B (es) 2025-03-20
NZ755287A (en) 2025-06-27
IL267451B1 (en) 2023-06-01
WO2018130868A8 (en) 2019-08-08
AU2017393082B2 (en) 2022-04-21
MX2019007338A (es) 2019-09-19
JP2020512389A (ja) 2020-04-23
EP3555100A4 (en) 2020-06-10
EP3555100A1 (en) 2019-10-23
CN110382501A (zh) 2019-10-25
CA3047684A1 (en) 2018-07-19
US20230134844A1 (en) 2023-05-04
US20180170941A1 (en) 2018-06-21
EA201991497A1 (ru) 2020-01-20
IL267451A (en) 2019-08-29
EP3555100B1 (en) 2023-05-10
JP7153938B2 (ja) 2022-10-17

Similar Documents

Publication Publication Date Title
IL278053B1 (en) Peptide macrocycles against acinetobacter baumannii
IL267451B2 (en) Benzodiazepine derivatives, compounds, and methods for treating cognitive impairment
AU2014368961B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
IL256354B (en) Benzodiazepine derivatives, compositions, and uses thereof for treating cognitive impairment
IL294031A (en) History of benzodiazepines, preparations and methods for the treatment of cognitive impairment
US11505555B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2023324882A1 (en) Benzazepine derivatives, compositions, and methods for treating cognitive impairment
HK40077472A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
OA20303A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
OA19667A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
HK1230170B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment